SCHEMBL22401172

SCHEMBL22401172

COC1CCC([C@@H](C)n2c(C)c(C(=O)O)c3ccccc32)CC1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 19/20 0.56
▸ KDM4E B2RXH2 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22401173 1.00 EZH2 (0.56) EZH2KDM4EGAA
SCHEMBL23606586 0.90 EZH2 (0.58) EZH2
SCHEMBL29966180 0.90 EZH2 (0.58) EZH2
SCHEMBL23672074 0.89 EZH2 (0.60) EZH2
SCHEMBL23682259 0.89 EZH2 (0.60) EZH2
SCHEMBL22401114 0.87 EZH2 (0.55) EZH2
SCHEMBL22401116 0.87 EZH2 (0.55) EZH2
SCHEMBL23581298 0.85 EZH2 (0.46) EZH2
SCHEMBL23581300 0.85 EZH2 (0.46) EZH2
SCHEMBL29741633 0.85 EZH2 (0.46) EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 — — US disclosed
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2022-10-04 — — US disclosed
EP-3707136-B1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2022-05-04 — — EP disclosed
EP-3707136-B1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2022-05-04 — — EP disclosed
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2021-07-29 — — US disclosed
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2021-07-29 — — US disclosed
WO-2021129629-A1 ZESTE ENHANCER HOMOLOGUE 2 INHIBITOR AND USE THEREOF 四川海思科制药有限公司 2021-07-01 — — WO disclosed
EP-3707136-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2020-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459315-B2 Modulators of methyl modifying enzymes, compositions and uses thereof TPMT, TET1, TET2 EZH2 150/4885KDM4E 93/4885GAA 222/4885
US-20210230148-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TPMT, TET1, TET2 EZH2 150/4885KDM4E 93/4885GAA 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback